ALK and non-small cell lung carcinoma: While avoiding ICIs in the initial treatment approach to patients with advanced NSCLC and an oncogenic driver—such as an activating EGFR mutation [35] or ALK fusions [36]—is established, it is still worth considering how these patients fare when treated with ICIs after progression on tyrosine kinase inhibitors (TKIs).